Physician profile
Christopher Edward Bowman
NPI 1649231606
$6,739.57
in general payments reported to CMS, 2019-2025
46 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $199 · 2021: $109 · 2022: $1,067 · 2023: $1,198 · 2024: $1,299 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,207.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $982.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $664.45 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $639.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $621.74 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $440.24 | 2022-2025 | |
| Dexcom, INC. | $384.12 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $237.35 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.36 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $209.30 | 2019-2022 | |
| Amgen INC. | $207.65 | 2019-2025 | Evenity, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $204.19 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.31 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $184.76 | 2019-2023 | |
| Pfizer INC. | $160.30 | 2019-2025 | |
| Glaxosmithkline, LLC. | $143.33 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.